We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BROS icon
251
Dutch Bros
BROS
$8.86B
$600K 0.01%
+18,742
New +$661K
AVXL icon
252
Anavex Life Sciences
AVXL
$231M
$599K 0.01%
105,484
+23,594
+29% +$136K
MITK icon
253
Mitek Systems
MITK
$756M
$597K 0.01%
+68,913
New +$698K
TTWO icon
254
Take-Two Interactive
TTWO
$46.1B
$582K 0.01%
3,785
+2,484
+191% +$377K
UTI icon
255
Universal Technical Institute
UTI
$2.26B
$581K 0.01%
+35,726
New +$612K
SPOK icon
256
Spok Holdings
SPOK
$229M
$577K 0.01%
+38,344
New +$583K
CRI icon
257
Carter's
CRI
$1.43B
$576K 0.01%
+8,867
New +$570K
ACCO icon
258
Acco Brands
ACCO
$399M
$568K 0.01%
+103,905
New +$525K
REI icon
259
Ring Energy
REI
$307M
$567K 0.01%
+354,659
New +$634K
POST icon
260
Post Holdings
POST
$4.42B
$561K 0.01%
4,850
+2,853
+143% +$320K
RDN icon
261
Radian Group
RDN
$5.28B
$560K 0.01%
+16,147
New +$559K
ACI icon
262
Albertsons Companies
ACI
$5.91B
$556K 0.01%
30,061
-4,347
-13% -$85.1K
CYRX icon
263
CryoPort
CYRX
$753M
$553K 0.01%
68,143
+38,161
+127% +$312K
SBUX icon
264
Starbucks
SBUX
$119B
$552K 0.01%
+5,665
New +$486K
BFAM icon
265
Bright Horizons
BFAM
$4.35B
$552K 0.01%
+3,937
New +$509K
AMR icon
266
Alpha Metallurgical Resources
AMR
$1.77B
$548K 0.01%
+2,319
New +$592K
MDXG icon
267
MiMedx Group
MDXG
$630M
$547K 0.01%
+92,514
New +$613K
OKE icon
268
Oneok
OKE
$56.7B
$544K 0.01%
+5,970
New +$519K
ACAD icon
269
Acadia Pharmaceuticals
ACAD
$4.51B
$541K 0.01%
+35,154
New +$586K
PFG icon
270
Principal Financial Group
PFG
$24.3B
$538K 0.01%
+6,268
New +$506K
BSY icon
271
Bentley Systems
BSY
$11.2B
$538K 0.01%
+10,588
New +$521K
PTON icon
272
Peloton Interactive
PTON
$2.85B
$529K 0.01%
113,093
+29,837
+36% +$117K
PAYC icon
273
Paycom
PAYC
$7.88B
$521K 0.01%
+3,126
New +$500K
SNBR
274
DELISTED
Sleep Number
SNBR
$518K 0.01%
+28,275
New +$370K
RICK icon
275
RCI Hospitality Holdings
RICK
$202M
$518K 0.01%
+11,627
New +$521K
9 10
11
12 13

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.